Dafalgan DOLO 500 mg, Brausetabletten

7680692650016 CH-69265 Brausetabletten

Associated product:

DAFALGAN Dolo cpr eff 500 mg 16 pce
Dafalgan DOLO 500 mg, Brausetabletten
Dafalgan DOLO 500 mg, Brausetabletten
Dafalgan DOLO 500 mg, Brausetabletten
1 / 3
google

Article details

Package size
16
Selling units
16
Measure
Tablette(n)
Galenic form
Brausetabletten
Galenic group
Brausetabletten

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
17/06/2025
Patient information leaflet
Français
17/06/2025
Patient information leaflet
Italien
17/06/2025
Summary of Product Characteristics
Allemand
17/06/2025
Summary of Product Characteristics
Français
17/06/2025
Summary of Product Characteristics
Italien
17/06/2025

Detailed composition

Substance Quantity Type Category
(N/A)
500.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
126.1 MG Substance HBESI
(N/A)
50.0 MG Substance HBESI
(N/A)
- Substance AROMA
(N/A)
0.83 MG Substance HBESI
(N/A)
0.96 MG Substance HBESI
(N/A)
0.28 MG Substance HBESI
(N/A)
- Substance HIMDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
197.0 MG Substance HBESI

Authorization holder

UPSA Switzerland AG

6300 Zug

Authorization information

Swissmedic authorization number
69265
Drug name
Dafalgan DOLO, Brausetabletten
Galenic form
BRAT
ATC Code
N02BE01
Authorization status
Z
Dispensing category
D
First authorization
01/05/2024
Authorization expiration date
30/04/2029
IT Number
01.01.1.
Domain
Human medicine
Field of application
Analgetikum, Antipyretikum

Package details

Description (FR)
DAFALGAN Dolo cpr eff 500 mg 16 pce
Description (DE)
DAFALGAN Dolo Brausetabl 500 mg 16 Stk
Market launch
01/05/2024
Narcotic (BTM)
No